Bristol Myers Squibb (NYSE:BMY) Stock Price Target Raised at Rothschild & Co Redburn

Key Points

• Rothschild & Co Redburn raised Bristol Myers Squibb’s price target from $51 to $53 but maintained a “neutral” rating, implying approximately 10.45% downside from the $59.18 share price.
• Analyst sentiment remains cautious: BMY has an overall “Hold” consensus rating and a $64.96 average price target, with recent downgrades from UBS and Jefferies and a lower target from Cantor Fitzgerald.
• Bristol Myers Squibb recently exceeded quarterly expectations, reporting $2.04 in EPS versus a $1.60 consensus estimate and $12.97 billion in revenue, up 5.7% year over year.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) had its target price upped by analysts at Rothschild & Co Redburn from $51.00 to $53.00 in a note issued to investors on Thursday. The brokerage currently has a "neutral" rating on the biopharmaceutical company's stock. Rothschild & Co Redburn's price target suggests a potential downside of 10.45% from the stock's current price.

BMY has been the topic of a number of other research reports. UBS Group cut Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a research report on Wednesday, August 5th. Cantor Fitzgerald cut their price objective on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a "neutral" rating for the company in a research report on Thursday. HSBC reaffirmed a "hold" rating and set a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a report on Thursday, September 10th. Jefferies Financial Group downgraded Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings raised Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, August 18th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $64.96.

Bristol Myers Squibb Trading Down 0.7%

Shares of NYSE BMY traded down $0.40 during trading on Thursday, reaching $59.18. The stock had a trading volume of 6,207,278 shares, compared to its average volume of 11,985,270. The business's 50-day moving average price is $64.27 and its 200-day moving average price is $60.28. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The company has a market cap of $120.89 billion, a P/E ratio of 13.04, a PEG ratio of 0.28 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business had revenue of $12.97 billion during the quarter, compared to analysts' expectations of $11.74 billion. During the same quarter last year, the business posted $1.46 EPS. The business's quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts predict that Bristol Myers Squibb will post 6.95 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company's stock, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.05% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of hedge funds have recently made changes to their positions in the business. Davis Asset Management L.P. bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at $27,000. Addison Advisors LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at about $32,000. Bayban bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $31,000. Groupe la Francaise lifted its stake in shares of Bristol Myers Squibb by 562.9% in the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 501 shares during the period. Finally, Kilter Group LLC bought a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $35,000. Institutional investors own 76.41% of the company's stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase 3 Zenbexus data: Bristol Myers reported that Zenbexus (iberdomide), combined with daratumumab and dexamethasone, delivered superior progression-free survival versus standard of care in relapsed or refractory multiple myeloma. The EXCALIBER-RRMM results reportedly reduced the risk of progression or death by 51% and produced high minimal residual disease-negative complete response rates, supporting the potential for accelerated approval and future revenue growth. What Could Bristol Myers Squibb Phase 3 Myeloma Data Mean For Investors?
• Positive Sentiment: Pipeline and commercial support: Coverage highlights Zenbexus as a potential growth driver, while Reblozyl’s expanding sales and additional indications may help offset declines from older products. Investors are also attracted to BMY’s profitability, relatively low valuation and high dividend yield. High-Yield Stocks to Buy in October
• Neutral Sentiment: Analyst opinions are mixed: J.P. Morgan issued a Buy rating, while Scotiabank maintained a Hold rating. The split suggests that Zenbexus’s clinical progress is encouraging, but investors remain cautious about execution, competition and the company’s longer-term growth outlook. J.P. Morgan Buy Rating
• Negative Sentiment: Price-target cuts weigh on sentiment: Morgan Stanley assigned a Sell rating, and Cantor Fitzgerald lowered its price target from $59 to $53 while keeping a Neutral rating. These calls indicate concern that the positive pipeline news may already be reflected in the stock or may not fully offset product concentration and competitive risks. Morgan Stanley Sell Rating

Bristol Myers Squibb Company Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb's portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.